Is CRISPR Therapeutics Stock Yesterday's News? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
10 stocks we like better than CRISPR Therapeutics › CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, on optimism about the potential approval of its first gene editing therapy. That candidate eventually won the regulatory nod and is commercialized as Casgevy, a gene editing treatment for blood disorders. But the biotech stock has spent recent years declining, and though it's rebounded somewhat this year, it still is down more than 60% from its 2021 peak. Meanwhile, Casgevy hasn't yet brought in significant revenue for the company. Is CRISPR Therapeutics yesterday's news? First, let's talk a bit about this company's technology and why it generated so much excitement prior to the first product approval. CRISPR Therapeutics' name clearly reflects its business. The company uses a process called CRISPR gene editing throughout its pipeline, and it involves cutting DNA at a specific location so that a natural
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors [Yahoo! Finance]Yahoo! Finance
- 3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.MarketBeat
- CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $86.00 price target on the stock.MarketBeat
- CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic MalignanciesGlobeNewswire
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 12/23/25 - Form 4
- 12/22/25 - Form 4
- 12/22/25 - Form 144
- CRSP's page on the SEC website